Effect of intensive glycemic control on cardiovascular outcomes and all-cause mortality in type 2 diabetes: Overview and metaanalysis of five trials

Diabetes Research and Clinical Practice

Volumn 86, Issue SUPLL.1, 2009, Pages

  Tkáč, Ivan ^a  

^a P J AFÁRIK UNIVERSITY   (Slovakia)

Author keywords

Cardiovascular disease; Glucose lowering treatment; Metaanalysis of randomized trials; Type 2 diabetes mellitus

Indexed keywords

ADVANCED GLYCATION END PRODUCT; GLICLAZIDE; HEMOGLOBIN A1C; INDAPAMIDE PLUS PERINDOPRIL; INSULIN; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE;

ACUTE CORONARY SYNDROME; ALBUMINURIA; ARTICLE; ATHEROSCLEROSIS; BELOW KNEE AMPUTATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBRAL ARTERY DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIABETIC NEPHROPATHY; GLYCEMIC CONTROL; HEART INFARCTION; HUMAN; HYPOGLYCEMIA; META ANALYSIS; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SUDDEN DEATH; SYSTEMATIC REVIEW; WEIGHT GAIN;

EID: 72149087737     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8227(09)70011-7     Document Type: Article

References (20)

1. Diabetes Control and Complicatins Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329 (1993) 304-309
2. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853
3. Stratton I.M., Adler A.I., Neil A.W., Matthews D.R., Manley S.E., Cull C.A., et al., on behalf of the UK Prospective Diabetes Study Group. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Br Med J 321 (2000) 405-412
4. Selvin E., Wattanakit K., Steffes M.W., Coresh J., and Sharrett A.R. HbA1c and peripheral arterial disease in diabetes. The Atherosclerosis Risk in Communities study. Diabetes Care 29 (2006) 877-882
5. Selvin E., Marinopoulos S., Berkenblit G., Rami T., Brancati F.L., Powe N.R., et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 141 (2004) 421-431
6. 1c with cardiovascular disease and mortality in adults: The European Prospective Investigation into Cancer in Norfolk. Ann Intern Med 141 (2004) 413-420
7. Jorgensen L., Jenssen T., Joakimsen O., Heuch I., Ingebretsen O.C., and Jacobsen B.K. Glycated hemoglobin is strongly related to the prevalence of carotid artery plaques with high echogenicity in nondiabetic individuals. The Tromso Study. Circulation 110 (2004) 466-470
8. Muntner P., DeSalvo K.B., Wildman R.P., Desalvo K.B., Chen J., and Fonseca V. Relationship between HbA1c level and peripheral arterial disease. Diabetes Care 28 (2005) 1981-1987
9. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352 (1998) 854-865
10. Dormandy J.A., Charbonnel B., Eckland D., Erdmann E., Massi-Benedetti M., Moules I.K., et al., on behalf of the PROactive Investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascuar Events): a randomised controlled trial. Lancet 366 (2005) 1279-1289
11. Wilcox R., Bousser M.G., Betteridge J., Schernthaner G., Pirags V., Kupfer S., et al., on behalf of the PROactive Investigators. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke. Results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke 38 (2007) 865-873
12. Erdmann E., Dormandy J.A., Charbonnel B., Massi-Benedetti M., Moules I.K., Skene A.M., and on behalf of the PROactive Investigators. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction. Results from the PROactive (PROactive 5) Study. J Am Coll Cardiol 49 (2007) 1772-1780
13. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358 (2008) 2545-2559
14. The ADVANCE Collaborative Group. Intensive blood glucose and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358 (2008) 2560-2572
15. Duckworth W., Abraira C., Moritz T., Reda D., Emanuele N., Reaven P.D., et al., for the VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360 (2009) 129-139
16. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353 (2005) 2643-2653
17. Holman R.R., Paul S.K., Bethel M.A., Matthews D.R., and Neil A.W. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359 (2008) 1577-1589
18. Gaede P., Lund-Andersen H., Parving H.H., and Pedersen O. Effects of multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 358 (2008) 580-591
19. Doria A., Wojcik J., Xu R., Gervino E.V., Hauser T.H., Johnstone M.T., et al. Interaction between poor glycemic control and 9p21 locus on risk of coronary artery disease in type 2 diabetes. J Am Med Assoc 300 (2008) 2389 2297
20. Skyler J.S., Bergenstal R., Bonow R.O., Buse J., Deedwania P., Gale E.M., et al. Intensive glycemic control and the prevention of cardiovascular events: Implications of the ACCORD, ADVANCE and VA Diabetes trials. A position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care 32 (2009) 187-192